Scharf Eugene L
Department of Neurology, Mayo Clinic, Rochester, Minnesota.
Cannabis Cannabinoid Res. 2017 Oct 1;2(1):259-264. doi: 10.1089/can.2017.0033. eCollection 2017.
The endocannabinoid system (ECS) regulates functions throughout human physiology, including neuropsychiatric, cardiovascular, autonomic, metabolic, and inflammatory states. The complex cellular interactions regulated by the ECS suggest a potential for vascular disease and stroke prevention by augmenting central nervous and immune cell endocannabinoid signaling. The endocannabinoid N-arachidonoylethanolamine (anandamide) plays a central role in augmenting these processes in cerebrovascular and neurometabolic disease. Furthermore, cannabidiol (CBD), a nonpsychoactive constituent of , is an immediate therapeutic candidate both for potentiating endocannabinoid signaling and for acting at multiple pharmacological targets. This speculative synthesis explores the current state of knowledge of the ECS and suggests CBD as a therapeutic candidate for stroke prevention by exerting favorable augmentation of the homeostatic effects of the ECS and, in turn, improving the metabolic syndrome, while simultaneously stalling the development of atherosclerosis.
内源性大麻素系统(ECS)调节人体生理的各项功能,包括神经精神、心血管、自主神经、代谢和炎症状态。ECS所调节的复杂细胞相互作用表明,通过增强中枢神经和免疫细胞的内源性大麻素信号传导,有可能预防血管疾病和中风。内源性大麻素N-花生四烯酰乙醇胺(花生四烯酸乙醇胺)在增强脑血管和神经代谢疾病中的这些过程中起着核心作用。此外,大麻二酚(CBD)是大麻的一种无精神活性成分,既是增强内源性大麻素信号传导的直接治疗候选药物,也是作用于多个药理学靶点的药物。这一推测性综述探讨了ECS的当前知识状态,并提出CBD作为预防中风的治疗候选药物,通过有利地增强ECS的稳态作用,进而改善代谢综合征,同时阻止动脉粥样硬化的发展。